Forberedelse og oppstart av klinisk utprøving av ny immunterapi mot ulike kreftformer

Offentlig prosjektsammendrag

Zelluna Immunotherapy is a company developing novel cellular cancer immunotherapies for treatment of a wide range of solid tumors. The therapies are designed to overcome some of the limitations seen with current therapies and provide deep and durable responses in patients. In this project, Zelluna aims to conduct the first human clinical trial with it’s lead product candidate – ZI-MA4-1. To achieve this aim we will establish and finalize preclinical experiments, establish GMP compliant manufacturing, obtain approval from regulatory authorities and conduct a first-in-human clinical trial. Obtaining the first clinical data is a major milestone and inflection point for Zelluna and a successful outcome of this project will enable further development of the lead product along with additional products that may benefit a large number of cancer patients globally.